A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual’s risk of death from lung cancer. The study supports the hypothesis that there is a hormonal influence on lung cancer and that estrogen levels play a role in lung cancer patients’ prognosis.